ENvue Medical shares surge 34.56% premarket on U-Deliver partnership and NHS product inclusion.

ENvue Medical (FEED) surged 34.56% in premarket trading following a series of positive developments. The stock’s sharp rise was driven by a partnership with U-Deliver to distribute its ENFit syringes nationwide via digital and wholesale channels, enhancing product accessibility. Additionally, the company secured the UroShield Kit’s inclusion in the UK’s NHS reimbursement system and announced the appointment of Marc Waldman, a seasoned medical device executive, to lead U.S. commercial strategy. These announcements underscored ENvue’s expansion efforts and strategic realignment toward its ENvue feeding tube system. While Bank of America’s minor share sale was noted, its limited impact contrasted with the broader bullish catalysts. The stock’s premarket jump aligns with its undervalued status highlighted in market analyses.